Demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variant Researchers at University of Alabama at Birmingham (UAB), Texas Biomedical Research Institute and Aridis Pharmaceuticals discovered a neutralizing monoclonal antibody that potentially acts as a potent universal coronavirus therapy against SARS-CoV-2 and all its variants of concern,…..
A 100% French nasal vaccine against COVID-19 yields positive pre-clinical results In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus. The vaccine candidate, developed…..
Evonik delivers first lipids from German facility to BioNTech The German company Evonik is delivering first batches of urgently needed lipids used in production of COVID-19 vaccine to BioNTech on April 22. Initially, delivery was scheduled to start in the middle of the year. But, specialists at Evonik’s Hanau site…..
Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..
EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of…..
NIH begins large clinical trial to test immune modulators for treatment of COVID-19 The National Institutes of Health (NIH) has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response…..
HexaPro: a new tool to speed up Covid-19 vaccine production ? Most coronavirus vaccine candidates train the human immune system to recognize the spike protein on the surface of the SARS-CoV-2 virus in order to fight infection. A scientific team at The University of Texas at Austin has successfully redesigned…..
Trend Chart On Innovative Bioindustries - July 2020, 29th FEATURE STORY GSK and CureVac announce strategic mRNA technology collaboration GSK and CureVac announced on July 20th the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting…..
Trend Chart On Innovative Bioindustries - June 2020, 2nd FEATURE STORY ● Novartis snags EU nod for SMA gene therapy After a manufacturing-related delay, Novartis has won conditional approval in the EU for Zolgensma®, the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and…..
